tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
PremiumCompany AnnouncementsCorcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
1M ago
Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant
Premium
Company Announcements
Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant
1M ago
Corcept Therapeutics: Buy Rating Backed by Promising Developments in Glucocorticoid Modulation and Oncology Expansion
Premium
Ratings
Corcept Therapeutics: Buy Rating Backed by Promising Developments in Glucocorticoid Modulation and Oncology Expansion
1M ago
Corcept Therapeutics price target lowered to $137 from $142 at Canaccord
PremiumThe FlyCorcept Therapeutics price target lowered to $137 from $142 at Canaccord
2M ago
Corcept Therapeutics: Buy Rating Backed by Strategic Growth Initiatives and Promising Product Launches
Premium
Ratings
Corcept Therapeutics: Buy Rating Backed by Strategic Growth Initiatives and Promising Product Launches
2M ago
Corcept Therapeutics Reports Revenue Growth Amid Rising Expenses
Premium
Company Announcements
Corcept Therapeutics Reports Revenue Growth Amid Rising Expenses
2M ago
Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
PremiumCompany AnnouncementsCorcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
2M ago
Corcept Therapeutics’ ALS Study: A Potential Game-Changer?
Premium
Company Announcements
Corcept Therapeutics’ ALS Study: A Potential Game-Changer?
2M ago
Corcept Therapeutics Submits New Drug Application to FDA
Premium
Company Announcements
Corcept Therapeutics Submits New Drug Application to FDA
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100